Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 12/20 | 0.50 |
| ▸ | PRKCA | P17252 | 3/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
| ▸ | PRKCG | P05129 | 1/20 | 0.39 |
| ▸ | PRKCB | P05771 | 1/20 | 0.39 |
| ▸ | PRKCH | P24723 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.39 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.39 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6730548 | 0.90 | TOP1 (0.53) | TOP1PRKCACHEK1PRKD3PRKCG | |
| SCHEMBL6729840 | 0.86 | PRKCA (0.55) | TOP1PRKCACHEK1PRKD3PRKCG | |
| SCHEMBL8354004 | 0.77 | TOP1 (0.41) | TOP1PRKCQ | |
| SCHEMBL6730638 | 0.72 | TOP1 (0.68) | TOP1PRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL6729568 | 0.71 | TOP1 (0.62) | TOP1PRKCACHEK1DYRK1APAX8 | |
| SCHEMBL5828476 | 0.70 | PRKCA (0.54) | TOP1PRKCACHEK1PRKCQ | |
| SCHEMBL5828918 | 0.69 | PRKCA (0.41) | TOP1PRKCA | |
| SCHEMBL5828608 | 0.67 | PRKCA (0.49) | TOP1PRKCA | |
| SCHEMBL3969257 | 0.67 | TOP1 (1.00) | TOP1PRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL5827662 | 0.67 | PRKCA (0.49) | TOP1PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242508-A1 | Novel hydroxyalkyl indolocarbazole derivatives, preparation method and pharmaceutical compositions containing the same | LES LABORATOIRES SERVIER (FR) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242508-A1 | Novel hydroxyalkyl indolocarbazole derivatives, preparation method and pharmaceutical compositions containing the same | RDX, HAX1, HRH1 | TOP1 242/4885PRKCA 3832/4885CHEK1 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.